Life Science Leader Interview
The FDA unveiled a new approval pathway for bespoke gene editing therapies in February 2026. More than 3,200 trials are underway worldwide. Lower cost critical raw materials like viral vectors are now available at lower costs, bioprocessing solutions have made the technology accessible with easier tech transfer, and Point-of-Care cell therapy manufacturing enables global deployment of life-saving therapies. Today’s centralized manufacturing and bespoke development models can make advanced therapies difficult to scale affordably. That creates a gap between scientific feasibility and practical patient access.
The field’s most consequential conversations are happening behind closed doors, but Michael Kadan, PhD, MBA, chief operating officer, Vector BioMed, is speaking to PharmaCircle. The company’s pioneering expertise has shaped its latest platform designed to bring customized and ready-to-deploy lentiviral vectors, as well as gene-edited cell manufacturing workflows, closer to clinical settings while eliminating traditional cost and complexity barriers.
How do manufacturing location, vector supply, and workflow design shape who can realistically deliver CAR-T?
It starts and stops with manufacturing. In cell and gene therapy, manufacturing is not a back-end function. It determines whether a therapy can realistically reach patients. CAR-T depends on quality input materials, robust processes, trained operators, quality systems, logistics, and clinical coordination. If manufacturing is centralized, highly customized, expensive, and capacity-constrained, access will naturally be limited to the institutions and geographies that can manage that cost and complexity, and longer execution times may become untenable for patients.
Vector supply is one of the clearest examples. Lentiviral vectors are critical raw materials for many cell and gene therapy programs. Supplier-driven delays or cost barriers slow developers and clinical programs before the therapy ever reaches a patient. At Vector BioMed, this is the thinking behind LENTIVERSE™: one lentiviral vector platform, two paths to advance cures. VectorCraft supports custom lentiviral vector development and manufacturing programs with specific therapeutic payloads. Developers can move novel therapeutic ideas from gene sequence to clinic-ready in under 12 months. LaunchSuite is a ready-to-deploy solution designed to support CAR-T manufacturing with characterized cGMP vectors targeting validated therapeutic targets, coupled with a simple and robust cell manufacturing process.
Workflow design is equally important. A process that only works in a specialized industrial setting is fundamentally different from one that can be standardized, transferred, and reproduced closer to clinical care. The goal is not to compromise quality. It is to embed quality into systems that are easier to operate and deploy.
The field needs to move from industrialization alone to operationalization: practical systems that clinicians, operators, and developers can use where and when they need them. That is how manufacturing location, vector access, and workflow design become patient-access issues.
How is a new class of service-based companies treating manufacturing as a patient-access problem rather than a margin opportunity?
The next-generation service supplier cannot simply be a capacity provider. It has to be an access partner. Traditional development and manufacturing models have often made advanced therapies expensive, slow, and difficult to scale. Those barriers ultimately land, indirectly, on patients. If development costs are too high, manufacturing slots are limited, or critical materials are unavailable, therapies do not move forward quickly enough or broadly enough.
A service model that is truly aligned with patient access looks different. It focuses on lowering cost, simplifying technology (where it makes sense), making critical materials available, and creating workflows that can be reproduced across sites and regions. It also requires a different economic model — one built around transparency and adoption rather than hidden fees, long-term royalties, or unnecessary complexity.
That is part of what we are working to demonstrate with LENTIVERSE. VectorCraft supports custom lentiviral vector development and manufacturing. LaunchSuite supports ready-to-deploy CAR-T manufacturing. Different needs, same objective: make the path from concept to clinic more practical, more affordable, and more reproducible. Our platform is built around transparent economics — no hidden long-term licensing fees or royalties — because those costs quietly contribute to therapy pricing in ways that ultimately reach patients. Affordability and sustainability are inseparable. Broad adoption is only possible if the development model and the cost of the marketed therapeutic make sense together.
What would it actually take to get clinical and gene therapy options in front of the clinicians and patients who need them now?
If a clinician does not know a trial exists, a patient may never hear about it. That is the most direct way to describe where the gap lives. Important advances are happening across cell and gene therapy, but much of that information still moves through closed industry environments. Developers, manufacturers, suppliers, and investors may be aware of what is changing, but clinicians and patients are not always connected to that information in a timely or useful way.
If an academic medical center does not know that enabling technologies or lower-cost manufacturing solutions are available, a program may never be launched. If a developer does not understand how to simplify its manufacturing strategy early, cost and time become barriers that slow the entire program.
The consequence is concrete: academic medical centers that don’t know lower-cost manufacturing options exist may never launch programs they could otherwise support.
Developers who don’t simplify their manufacturing strategy early enough pay for it in time and cost, and so do patients.
Solving this requires better connectivity between developers, clinicians, service providers, regulators, payers, patient advocacy groups, and health systems. It also requires practical education and programs, not only scientific presentations at industry meetings. Clinicians need actionable information: what therapies are available, what is emerging, where patients can be referred, and what infrastructure is required. No single organization can solve this alone. But the industry must become more vocal and more transparent about the tools and pathways that already exist.
How are patient advocacy organizations navigating the same information gap from the other side?
Patient advocacy organizations are often trying to solve the access problem from the most urgent side: the patient side. They hear directly from patients and families searching for options — looking for a trial, a specialist, a clinical center, or just a clearer understanding of whether a therapy could apply to them. But the information is often fragmented. Trial information may be difficult to interpret. Referral pathways may not be obvious. Emerging therapies may be discussed in industry settings long before patients or community physicians understand what they mean.
These groups should not be expected to carry that burden alone. They need clearer information from industry, stronger connections with clinical programs, and better visibility into what is actually moving toward patients.
We treat patient advocacy organizations as essential stakeholders in the access ecosystem, not as an afterthought. They help identify needs, communicate with patients, and keep the work focused on its real purpose.
What are alternatives to centralized manufacturing and bespoke development models?
The principle is straightforward: reduce unnecessary complexity while maintaining quality. The tools already exist. The question is whether developers are using them early enough.
Point-of-care or near-patient manufacturing is one important direction, bringing parts of the process closer to the clinical setting. This is not appropriate for every therapy or every region immediately, but it can reduce logistical barriers and support broader deployment. Our work supporting initiatives led by our nonprofit partner Caring Cross — in Brazil with Fiocruz and INCA, and in Turkey with Koç Healthcare — reflects that in practice.
Modular, standardized workflows are another path. Quality-by-design systems, standardized materials, validated workflows, and reproducible processes help developers move faster and more affordably without every program reinventing every step.
Critical material access is also essential. For many programs, lentiviral vector availability determines whether development moves efficiently or stalls. Some programs need a highly tailored lentiviral vector built around a specific therapeutic payload. Others need a faster, standardized route for CAR-T manufacturing with characterized CGMP vectors, documentation, and workflows that support decentralized production. Centralized manufacturing will remain appropriate in many cases. But it should not be the only model available, and we do not think it will be.
How mature is this area and what still needs to be done?
The field is mature in some respects and still developing in others. Scientifically and clinically, CAR-T has proven that engineered cell therapies can produce profound responses in certain cancers. There are approved products, real-world experience, growing clinical data, and a broad pipeline.
Operationally, the field is still not where it needs to be. Manufacturing remains too expensive and too complex. Locations don’t reach far enough. Capacity is uneven. Critical materials can still create bottlenecks. Reimbursement remains difficult. Many clinicians outside major cell therapy centers are not connected to the latest options.
What still needs to be done is the systems work: lower-cost inputs, simplified workflows, stronger tech transfer, better clinical-site enablement, and more practical reimbursement models. The field also needs specialized suppliers that understand the full relationship between vector design, vector manufacturability, cell manufacturing performance, and patient access.
This is why the distinction between a broad-spectrum CDMO and a specialized lentiviral vector CVDMO (Contract Viral Development and Manufacturing Organization) matters. For advanced therapies, the vector cannot simply work in theory. It has to work in real-world therapeutic production, with quality, reproducibility, and economics that support patient access.
The next phase is not just about creating more advanced therapies. It is about making advanced therapies equitable and sustainable.
About PharmaCircle
PharmaCircle is a thought leader in drug delivery and formulation development, publishing the Weekly Intelligence Newsletter, which has a worldwide readership, and in-depth reports in all areas of drug delivery, including new and novel technologies and devices. PharmaCircle is a leading information provider to the pharmaceutical and medical device industries, providing business prospecting and analysis tools, pipeline and products intelligence, regulatory data, and other information solutions to our clients. PharmaCircle’s Premium database service delivers a comprehensive view into drug, biologics and combination product development and innovation, combining scientific, clinical, safety, regulatory, supply chain, and commercial data and insights into one solution. PharmaCircle recently launched MedTech Explorer, a hand-curated database that assembles the latest intelligence on medical devices, diagnostic tests and drug delivery device technologies in development and on the market. For more information about the content of this analysis, contact PharmaCircle’s Editorial Department at mailto:editorial@pharmacircle.com. For more information about PharmaCircle and our subscription database services, contact mailto:info@pharmacircle.com or visit our websites – http://www.pharmacircle.com and http://www.medtechexplorer.com.
